Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 943,218
  • Shares Outstanding, K 118,943
  • Annual Sales, $ 207,740 K
  • Annual Income, $ -143,590 K
  • 60-Month Beta 1.77
  • Price/Sales 2.58
  • Price/Cash Flow N/A
  • Price/Book 2.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.44
  • Number of Estimates 4
  • High Estimate -0.26
  • Low Estimate -0.53
  • Prior Year -0.91
  • Growth Rate Est. (year over year) +51.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.03 +31.51%
on 12/23/19
8.26 -4.00%
on 01/21/20
+1.75 (+28.32%)
since 12/20/19
3-Month
2.99 +165.22%
on 11/13/19
8.26 -4.00%
on 01/21/20
+3.78 (+91.08%)
since 10/21/19
52-Week
2.99 +165.22%
on 11/13/19
9.30 -14.73%
on 03/12/19
+1.54 (+24.10%)
since 01/18/19

Most Recent Stories

More News
Clovis Oncology is Among the Companies in the Biotechnology Industry with the Best Relative Performance (CLVS , AKBA , SAGE , FPRX , AGIO )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

AKBA : 7.93 (-1.25%)
CLVS : 9.35 (-5.08%)
SAGE : 73.27 (-4.10%)
Relatively Good Performance Detected in Shares of Akebia Therapeut in the Biotechnology Industry (AKBA , FOLD , NVTA , BPMC , CTMX )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

AKBA : 7.93 (-1.25%)
FOLD : 9.78 (-6.00%)
NVTA : 18.75 (-4.48%)
Akebia Therapeut Has Returned 57.5% Since SmarTrend Recommendation (AKBA)

SmarTrend identified an Uptrend for Akebia Therapeut (NASDAQ:AKBA) on November 25th, 2019 at $4.54. In approximately 2 months, Akebia Therapeut has returned 57.49% as of today's recent price of $7.15....

AKBA : 7.93 (-1.25%)
Shares of AKBA Up 45.8% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Akebia Therapeut (NASDAQ:AKBA) on November 25th, 2019 at $4.54. In approximately 1 month, Akebia Therapeut has returned 45.81% as of today's recent price of $6.62.

AKBA : 7.93 (-1.25%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted six newly-hired employees...

AKBA : 7.93 (-1.25%)
Relatively Good Performance Detected in Shares of Epizyme Inc in the Biotechnology Industry (EPZM , AIMT , AKBA , ARWR, ATRA )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

AIMT : 33.08 (-5.27%)
AKBA : 7.93 (-1.25%)
EPZM : 26.01 (-2.66%)
ARWR : 47.59 (-15.65%)
SmarTrend Watching for Potential Pullback in Shares of Akebia Therapeut After 2.02% Gain

Akebia Therapeut (NASDAQ:AKBA) traded in a range yesterday that spanned from a low of $6.61 to a high of $6.90. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of...

AKBA : 7.93 (-1.25%)
Uptrend Call Working As Akebia Therapeut Stock Rises 45.2% (AKBA)

SmarTrend identified an Uptrend for Akebia Therapeut (NASDAQ:AKBA) on November 25th, 2019 at $4.54. In approximately 4 weeks, Akebia Therapeut has returned 45.15% as of today's recent price of $6.59.

AKBA : 7.93 (-1.25%)
40.7% Return Seen to Date on SmarTrend Akebia Therapeut Call (AKBA)

SmarTrend identified an Uptrend for Akebia Therapeut (NASDAQ:AKBA) on November 25th, 2019 at $4.54. In approximately 3 weeks, Akebia Therapeut has returned 40.75% as of today's recent price of $6.39.

AKBA : 7.93 (-1.25%)
Akebia Therapeut (AKBA)

SmarTrend identified a Downtrend for Akebia Therapeut (NASDAQ:AKBA) on September 30th, 2019 at $4.03. In approximately 2 months, Akebia Therapeut has returned 46.65% as of today's recent price of $5.91....

AKBA : 7.93 (-1.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade AKBA with:

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 8.40
1st Resistance Point 8.16
Last Price 7.93
1st Support Level 7.79
2nd Support Level 7.66

See More

52-Week High 9.30
Last Price 7.93
Fibonacci 61.8% 6.89
Fibonacci 50% 6.14
Fibonacci 38.2% 5.40
52-Week Low 2.99

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar